Hims & Hers Shares Surge 40.8% After Novo Nordisk Weight-Loss Deal Resolution
Hims & Hers Health shares jumped 40.79% to close at $22.16 after Novo Nordisk agreed to sell its weight-loss drug through the company’s telehealth platform following a patent dispute resolution. The platform serves over 2 million subscribers across all 50 states and certain European markets, offering prescription and over-the-counter treatments.
1. Stock Price Reaction
Shares of Hims & Hers Health surged 40.79% to close at $22.16, after hitting an intraday high of $23.51 and a low of $20.97. The stock’s 52-week range spans $13.74 to $70.43.
2. Novo Nordisk Partnership Details
Novo Nordisk will distribute its weight-loss drug through Hims & Hers’ telehealth platform following settlement of a patent violation dispute. This agreement expands the platform’s treatment portfolio, leveraging its telemedicine infrastructure and over 2 million subscribers across the U.S. and selected European markets.